Quintrio
Home

SERVICES-PREPACKAGED SOFTWARE

Firefly Neuroscience, Inc. Common Stock

AIFF

Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.

Last trade $0.9046
Day change +$0.0193 (+2.18%)
Day range $0.885 – $1.01
Volume 126,041
Market cap $14M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$14.02M
Price / earnings
—
Price / book
1.04×
Price / sales
6.81×
EV / sales
2.91×
EV / EBITDA
-0.77×

Profitability

Earnings per share
-$0.53
Return on assets
-53.57%
Return on equity
-61.63%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.48×
Quick ratio
4.45×
Cash ratio
3.97×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AIFF, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$647K$514K$485K$412K$388K$299K$43K$53K
Cost of revenue$122K$261K$264K$230K$242K$25K$0$0
Gross profit$525K$253K$221K$182K$146K$274K$43K$53K
Selling, general and administrative$1.68M$1.7M$1.81M$2.13M$2.27M$1.57M$1.8M$2.18M
Research and development$383K$525K$424K$456K$378K$336K$312K$437K
Total operating expenses$2.07M$2.23M$2.23M$2.68M$2.8M$1.91M$2.11M$3.49M
Operating income-$1.54M-$1.97M-$2.01M-$2.5M-$2.66M-$1.63M-$2.07M-$3.44M
Interest expense-$4K-$6K-$7K-$6K-$10K-$15K-$128K-$33K
Income before taxes-$1.48M-$1.98M-$2M-$2.48M-$2.64M-$1.83M-$12.93M-$3.78M
Income taxes$0$0$0$1K$0$4K$0-$2K
Net income-$1.48M-$1.98M-$2M-$2.48M-$2.64M-$1.83M-$12.93M-$3.78M
Net income attributable to common shareholders-$1.48M-$1.98M-$2.09M-$2.72M-$2.64M-$1.83M-$17.34M-$3.79M
EBITDA-$1.49M-$1.93M-$1.97M-$2.35M-$2.45M-$1.59M-$2.05M-$2.5M
Basic earnings per share-$0.07-$0.10-$0.13-$0.20-$0.20-$0.14-$1.74-$0.43
Diluted earnings per share-$0.07-$0.10-$0.13-$0.20-$0.20-$0.14-$1.74-$0.43

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.

GlobeNewswire Inc.

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.